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Chronic hypertension in pregnancy is defined by the American College of Obstetricians and Gynaecologists as systolic 
blood pressure (SBP) >140 mm Hg and/or diastolic blood pres-
sure >90 mm Hg, which has presented before pregnancy or 
before gestational week 20.1 Despite affecting a similar number 
of women as other hypertensive disorders of pregnancy, mater-
nal chronic hypertension receives relatively less research atten-
tion.2 Women with chronic hypertension are at increased risk 
of maternal and fetal morbidity and mortality.3 The problem of 
chronic hypertension in pregnancy is growing in parallel to the 
prevalence of increased maternal age,4 obesity,5 and metabolic 
syndrome.6 There is no consensus on the treatment of pregnant 
women with chronic hypertension and no generally accepted 
target blood pressure at which the risk of adverse complications 
to both mother and fetus is substantially reduced.7 Research into 
the cardiovascular complications associated with pregnancy 
in women with pre-existing hypertension is therefore needed.
Vascular remodeling plays a central role in maternal adap-
tation to pregnancy to accommodate the increase in cardiac 
output and regulate maternal blood pressure.8 Specifically, the 
uterine vasculature must undergo extensive structural and func-
tional changes to provide sufficient blood supply to the devel-
oping placenta and fetus. It is well established that deficient 
adaptation of the uterine vasculature leads to adverse pregnancy 
outcomes.9 We recently hypothesized that pre-existing mater-
nal cardiovascular disease would negatively affect the ability 
of the vasculature to suitably adapt to pregnancy and tested 
this hypothesis in the stroke-prone spontaneously hyperten-
sive rat (SHRSP). The SHRSP is a well-established rat model 
that mirrors many features of human hypertension-related 
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cardiovascular complications and has been used in research 
for >30 years.10 Some aspects of pregnancy in the SHRSP have 
already been briefly characterized11,12; however, the vascular 
adaptation to pregnancy has not been studied systematically. 
We have shown that the SHRSP presents with reduced litter 
size and increased loss of glycogen storage from the placenta 
associated with spontaneous deficient uterine artery remodeling 
and blood flow relative to the contrasting strain, Wistar–Kyoto 
(WKY), at gestational day (GD) 18.13
Activation of the innate immune system has been reported in 
both chronic hypertension14 and adverse pregnancy outcome.15 
Levels of the proinflammatory cytokine tumor necrosis factor-α 
(TNF-α) have been found to be increased in hypertensive sub-
jects16 and in women with severe hypertensive pregnancy com-
plications.17 Furthermore, TNF-α infusion induces vascular 
dysfunction in both humans and rodents.18,19 During pregnancy, 
TNF-α can be produced from a plethora of cell types but pre-
dominantly by activated monocytes/macrophages, T lympho-
cytes, natural killer (NK) cells, and invasive fetally derived 
extravillous trophoblasts.20 Antagonism of TNF-α signaling has 
not been used clinically to treat hypertension in pregnancy but 
has been shown to have therapeutic effects in preclinical models 
of pregnancy-induced hypertension.21,22
Here, we hypothesize that TNF-α provides a link between 
vascular dysfunction and adverse pregnancy outcome by play-
ing a causative role in the abnormal uterine vascular function 
and reduced litter size in the SHRSP at GD 18. We performed 
an intervention study using etanercept in pregnant SHRSP and 
sought to identify the source of excess TNF-α.
Methods
Most of the methods have been previously described by our group 
including the implantation of radiotelemetry probes,23 Doppler ultra-
sound,13 myography of the uterine arteries,13,24 and periodic acid–
Schiff stain of the placenta.13 Full details are found in the online-only 
Data Supplement.
Animals
Animals (SHRSP and WKY) were housed under controlled lighting 
(0700–1900 hours) and temperature (21±3 °C) and received a nor-
mal diet (rat and mouse no.1 maintenance diet; Special Diet Services, 
Grangemouth, United Kingdom) provided ad libitum. All animal pro-
cedures were approved by the Home Office according to the regula-
tions on experiments with animals in the United Kingdom (Project 
License Number 60/4286). Females were time-mated at 12 weeks of 
age (±4 days). Non-pregnant animals were age-matched at 15 weeks±4 
days (ie, 12 weeks of age+21 days of pregnancy). Day 0 of pregnancy 
was defined as the day that a coital plug was observed indicative of suc-
cessful mating having taken place. The number of rats used for a given 
experiment is indicated in the associated figure legend.
Etanercept Treatment
Animals were treated with etanercept 0.8 mg/kg (Wyeth 
Pharmaceuticals, Maidenhead, United Kingdom) diluted in sterile 
phosphate-buffered saline (Thermo Fisher Scientific, Paisley, United 
Kingdom) on GD 0, 6, 12, and 18 of pregnancy via SC injection. 
Vehicle-treated animals were subject to the same procedure using 
sterile phosphate-buffered saline (Thermo Fisher Scientific, Paisley, 
United Kingdom).
Data Analysis
Analysis of flow cytometry data was performed using FlowJo v.10 
where gates were applied according to fluorescence minus one 
control. For quantitative real-time PCR data, results were analyzed 
using the 2−ΔΔCT method. Statistical analysis was performed using 
GraphPad Prism v 4.0. Student t test and 1-way ANOVA followed 
by Tukey test were used to compare WKY and SHRSP and WKY, 
SHRSP, and SHRSP treated with etanercept. Radiotelemetry data 
were analyzed using 2-way ANOVA, and the difference in blood 
pressure between SHRSP and SHRSP treated with etanercept was 
analyzed by calculating the ΔSBP from GD 12–GD 21 followed by 
Student t test. P <0.05 was considered to be statistically significant 
for all experiments.
Results
TNF-α Is Increased in Pregnant SHRSP Relative  
to WKY
TNF-α was increased in plasma and urine from pregnant 
(GD 18) SHRSP relative to pregnant WKY (Figure 1A and 
1B). Increased secretion of TNF-α was also detected in media 
taken from placental tissue explants from GD 18 SHRSP 
(Figure 1C). Etanercept treatment in SHRSP did not signifi-
cantly alter TNF-α levels from GD 18 plasma samples or 
placental explant media (Figure S1). Gene expression of the 
main proinflammatory TNF-α receptor-1 (Tnfr1) was also 
significantly increased in the GD 18 uteroplacental unit from 
SHRSP relative to WKY (Figure 1D).
Etanercept Treatment Reduces Systolic Blood 
Pressure in the Pregnant SHRSP
Etanercept (0.8 mg/kg SC) was given at GD 0 of pregnancy 
and repeated at GD 6, 12, and 18, and the effect on blood 
pressure in the SHRSP relative to vehicle-treated controls was 
monitored using radiotelemetry. SHRSPs are hypertensive 
before and during pregnancy in contrast to the control WKY 
strain (Figure 2A and 2B). Etanercept had no effect on SHRSP 
blood pressure in early pregnancy (GD 0–12). After GD 12, 
there was a significant average decrease of 11.5 mm Hg in SBP 
in etanercept relative to vehicle-treated SHRSP (Figure 2A), 
which persisted until parturition. No significant difference 
between SHRSP and etanercept-treated SHRSP was observed 
in diastolic blood pressure (Figure 2B). Heart rate was not 
significantly different between groups (Figure S2A). Activity 
was significantly decreased in both SHRSP and SHRSP 
treated with etanercept relative to the WKY over the course of 
pregnancy (Figure S2B).
Etanercept Improves Placental Abnormality and 
Litter Size in the SHRSP
Placenta from SHRSP exhibited a significant decrease in glyco-
gen storage at GD 18 relative to the WKY (Figure 2C through 
2E). Etanercept treatment in the SHRSP restored periodic 
acid–Schiff–positive glycogen cells within the junctional zone 
of the placenta (Figure 2C through 2E). Litter size was sig-
nificantly increased by etanercept treatment in SHRSP (Figure 
2D). Concurrently, the number of dams, which presented 
with ≥1 resorptions, was decreased in SHRSP treated with 
etanercept (WKY, 30%; SHRSP, 66.7%; SHRSP treated with 
etanercept, 25%). Litter size was not related to the changes in 
blastocyst implantation as there was no difference in the num-
ber of implantation sites at GD 6 between the groups (Figure 
S3). Furthermore, there was no difference in fetal or placental 
weight between any of the groups (Figure S4).
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Etanercept Improves Abnormal Uterine Artery 
Function and Blood Flow in the Pregnant SHRSP
Pressure myography was used to construct pressure–diameter 
relationships to assess uterine artery properties from GD 18 
WKY, SHRSP, and SHRSP treated with etanercept. Etanercept 
treatment did not significantly alter the diameter or wall thick-
ness of the SHRSP uterine arteries (Figure S5). Investigation 
of uterine artery vasomotor function using wire myography 
showed that uterine arteries from pregnant SHRSP had a 
significantly increased contractile response to noradrenaline 
and a blunted endothelium-dependent vasorelaxation relative 
to the WKY (Figure 3A and 3B). In contrast, uterine arter-
ies from pregnant SHRSP treated with etanercept exhibited 
a marked reduction in contractile response that was not sig-
nificantly different from WKY and a significant increase in 
vasorelaxation to carbachol (Figure 3A and 3B). Etanercept 
treatment did not have a significant effect on mesenteric artery 
function in SHRSP (Figure S6).
These changes in uterine artery vasomotor function trans-
lated into improvements in uterine artery blood flow were 
assessed by Doppler ultrasound. Etanercept treatment par-
tially restored the physiological increase in diastolic volume 
over the course of pregnancy, which is present in the WKY 
but absent in the SHRSP (Figure 3C), resulting in significantly 
reduced uterine artery resistance index in etanercept-treated 
SHRSP relative to control SHRSP (Figure 3D).
NK Cells Are a Source of Excess TNF-α  
in the SHRSP
From the beneficial effects we observed in pregnancy out-
come and uterine artery function in SHRSP treated with 
etanercept, we deduced that excess TNF-α signaling played 
a causal role in the pathology observed during pregnancy 
in this model. Although TNF-α can be produced in some 
quantity from almost all cell types, we focused on one of the 
major producers, the immune cells, to identify the source(s) 
of excess TNF-α in the SHRSP. We designed a flow cytom-
etry panel to quantify immune cell populations in pregnant 
WKY and SHRSP in the maternal blood and placenta (Figure 
S7 and S8, full panel and Figure S9, gating strategy). Of the 
populations analyzed, NK cells (CD3− CD161+) were the most 
markedly increased in the SHRSP relative to WKY in both 
maternal circulation (Figure 4A) and placenta (Figure 4B and 
4C). Furthermore, we detected pregnancy-specific changes in 
peripheral CD3− CD161+ cells in maternal blood. In WKY, 
these cells were significantly decreased from nonpregnant to 
pregnant (GD 18) WKY (Figure 4D). In contrast, there was 
a significant increase in peripheral NK cells in SHRSP from 
nonpregnant to GD 18 (Figure 4D).
The significant increase in NK cells in the maternal cir-
culation and placenta of the SHRSP was a promising can-
didate as the source of excess TNF-α. Intracellular staining 
of CD161+ cells in both the maternal circulation (Figure 5A 
and 5B) and placenta (Figure 5C and 5D) showed that TNF-α 
production is significantly increased in the SHRSP relative to 
the WKY at GD 18. TNF-α production from CD3+ T cells or 
other CD45+ cells was not significantly different between the 
strains (Figure S10).
Etanercept Reduces Granzyme B Production From 
CD161+ Cells in the SHRSP Placenta
Etanercept treatment in the SHRSP significantly reduced the 
number of CD161+ NK cells present in the SHRSP placenta 
(Figure 6A) but not in the maternal circulation (Figure 6B). 
Within the placental CD161+ cells in SHRSP animals only, 
we identified a CD161 low (CD161Low) population and a 
CD161 positive (CD161+) population (Figure 6C). Reduction 
of CD161+ cells in the placenta from SHRSP treated with 
etanercept was associated with a significant increase in 
the CD161Low population (Figure 6D). The CD161+ popu-
lation had a characteristically cytotoxic phenotype where 
the majority of these cells stained positively for intracellu-
lar granzyme B from placenta in both SHRSP and SHRSP 
treated with etanercept. In contrast, the CD161Low popula-
tion had a significantly decreased proportion of granzyme B 
expression from placenta in both SHRSP and SHRSP treated 
with etanercept (Figure 6E and 6F). Therefore, etanercept 
treatment reduces CD161+ cells in the SHRSP placenta by 
Figure 1. Tumor necrosis factor-α (TNF-α)  
is increased in pregnant stroke-prone 
spontaneously hypertensive rat (SHRSP). 
TNF-α was measured in plasma (A) and 
urine (B) using ELISA (n=6; *P<0.05 vs 
Wistar–Kyoto [WKY]). Secretion of TNF-α (C) 
was increased from placental explants (n=5; 
*P<0.05 vs GD 18 WKY). Gene expression of 
TNF-α receptor-1 (Tnfr1; D) was measured 
in the uteroplacental unit (n=6; ***P<0.005 
vs GD 18 WKY). Data were analyzed by 
Student t test. CP indicates chorionic plate; 
Dx, decidua; Jx, junctional zone; and Lx, 
labyrinth.
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reducing the expression of CD161 receptor, which is associ-
ated with a reduction in granzyme B production.
Discussion
Etanercept treatment has beneficial effects on the placenta 
and litter size of the SHRSP through the improvement of uter-
ine artery function and uteroplacental blood flow. Etanercept 
antagonizes signaling from the excess TNF-α produced by 
a pregnancy-dependent increase in CD161+ NK cells found 
in the SHRSP and has direct effects on the placenta where it 
minimizes cytotoxic granzyme B from these CD161+ cells.
Etanercept has previously been shown to reduce blood 
pressure in a rat model of preeclampsia.21,25 In contrast, it 
had no effect on blood pressure in nonpregnant hypertensive 
Figure 2. Etanercept treatment reduces systolic blood (SBP) pressure and improves placental biology and pregnancy outcome in 
the stroke-prone spontaneously hypertensive rat (SHRSP). SBP (A) and diastolic blood pressure (DBP; B) were monitored using 
radiotelemetry in Wistar–Kyoto (WKY), SHRSP, and etanercept-treated SHRSP (n=4–6) from 7 d before pregnancy (gestational day [GD]−7 
to −1) and during pregnancy (GD 0–21). SHRSP and SHRSP treated with etanercept had significantly increased SBP and DBP relative 
to the WKY from GD−7 to GD 21 (*P<0.05 vs WKY analyzed by 2-way ANOVA). Etanercept-treated SHRSP had a significant decrease in 
SBP from GD 12–21 relative to vehicle-treated SHRSP (#P<0.05 vs SHRSP analyzed by ΔSBP GD 12–21 followed by a Student t test). 
Glycogen cell content in the junctional zone (Jx) of the placenta was assessed by counting the number of periodic acid–Schiff –positive 
cells in WKY, SHRSP, and SHRSP treated with etanercept (n=6). A representative uteroplacental unit for each group is shown in C and 
quantified in E (#P<0.05 vs SHRSP analyzed by 1-way ANOVA followed by a post hoc Tukey test). D, Litter size was counted at GD 18 in 
WKY, SHRSP, and etanercept (n=6–12; ##P<0.01 vs SHRSP analyzed by 1-way ANOVA followed by a post hoc Tukey test).
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female rats.26 These differing results show that etanercept has 
context-dependent effects on blood pressure, perhaps related 
to the extent or localization of inflammation. The average SBP 
reduction of 11.5 mm Hg in pregnant SHRSP treated with 
etanercept is comparable to the reduction in blood pressure 
seen in other rat models.21,25 As etanercept does not completely 
normalize blood pressure in the SHRSP; there must be other 
as-yet-unknown mechanisms that contribute to the hyper-
tension we observe in this model. In this study, the decrease 
in SBP is not present until after GD 12 in the SHRSP. This 
coincides with the development of the mature uteroplacental 
unit by GD 12, suggesting that the placenta may be the source 
of excess TNF-α. Reducing maternal blood pressure during 
pregnancy using antihypertensive agents has been related to 
fetal growth restriction.27 Importantly, in this study, the sig-
nificant reduction in SBP in late pregnancy has no negative 
impact on fetal growth as no significant difference in fetal 
weight was observed between vehicle- and etanercept-treated 
SHRSP. In fact, pregnancy outcome is improved in SHRSP 
treated with etanercept where there is a significant increase in 
litter size and a decrease in dams presenting with resorptions 
at GD 18. Etanercept treatment has been previously shown to 
reduce spontaneous pregnancy loss in a model of abnormal 
maternal inflammation during pregnancy.28
Etanercept treatment improves endothelium-dependent 
vasorelaxation in SHRSP uterine arteries. TNF-α has a well-
defined role in endothelial dysfunction by diminishing the 
bioavailability of vasodilator nitric oxide through the down-
regulation of the expression of the eNOS (endothelial NO 
synthase) pathway29,30 and through increased superoxide pro-
duction.31 Etanercept also significantly reduces the uterine 
artery vasocontractile response to noradrenaline in our model. 
Figure 3. Etanercept treatment significantly improves gestational day (GD) 18 uterine artery function and blood flow in the stroke-prone 
spontaneously hypertensive rat (SHRSP). Isolated uterine artery function was assessed using wire myography in Wistar–Kyoto (WKY), 
SHRSP, and SHRSP treated with etanercept (n=6) at GD 18 of pregnancy. Uterine artery contractile response was determined using 
noradrenaline (NA; A), and endothelium-dependent vasorelaxation was assessed using carbachol response (B). Uterine arteries from 
etanercept-treated SHRSP had a significantly reduced contractile response to NA (A) relative to SHRSP (##P<0.01 vs SHRSP analyzed 
by calculating the area under the curve followed by 1-way ANOVA) and a significantly increased relaxation response to carbachol (B) at 
1×10−5 mol/L (#P<0.05 vs SHRSP analyzed by Student t test). Uterine artery blood flow was assessed using Doppler ultrasound in WKY, 
SHRSP, and SHRSP treated with etanercept (n=6) at GD 6, 12, and 18. Representative Doppler traces are shown in (C). The pregnancy-
induced increase in diastolic blood flow which is present in the WKY but reduced in SHRSP is partially restored in SHRSP treated with 
etanercept (C) resulting in a significant reduction in resistance index at GD 18 (D; ##P<0.01 vs SHRSP analyzed by 1-way ANOVA 
followed by a post hoc Tukey test).
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Changes in the vascular response to noradrenaline in etaner-
cept-treated SHRSP could indicate changes in sympathetic 
nervous system activity in these animals. As a crude measure 
of sympathetic drive, we analyzed heart rate variability that 
showed a significant reduction over pregnancy in etanercept-
treated SHRSP (data not shown). However, these results are 
difficult to interpret taking into account the change in heart 
rate over pregnancy. TNF-α has been shown to induce the pro-
duction of vasoconstrictor endothelin-132 and can alter calcium 
handling.33 In the context of the experiment presented here, 
etanercept may have a role in the downregulation or desensi-
tization of contractile adrenoreceptors to blunt the response 
to noradrenaline. In vascular function studies using resistance 
vessels from ovarectomized female rats where systemic TNF-
α is elevated, etanercept treatment reduces contractility and 
improves endothelium-dependent vasorelaxation.34 In keep-
ing with the improvement in uterine artery function in the 
SHRSP, uteroplacental blood flow is partially restored with 
etanercept treatment. Correction of deficient uteroplacental 
blood flow during pregnancy using a TNF-α antagonist has 
not previously been shown in the literature. However, plasma 
TNF-α has been shown to have a positive correlation with 
abnormal uterine artery resistance index and the presence 
of notching in humans.35 We have previously hypothesized 
that deficient uteroplacental perfusion in SHRSP leads to 
the premature utilization of glycogen stores in the placenta.13 
In agreement, improvement of uteroplacental blood flow in 
etanercept-treated SHRSP restores the presence of placental 
glycogen cells at GD 18.
In experiments into the source of excess TNF-α in preg-
nant SHRSP, we found that the number of CD3− CD161+ NK 
cells was increased in a pregnancy-dependent manner in the 
SHRSP but not in the control WKY. NK cells are part of the 
innate immune system with potent cytotoxic ability. In the con-
text of hypertension, the NK cell gene locus has been shown 
to confer susceptibility to L-NAME (Nω-nitro-l-arginine 
methyl ester hydrochloride)–induced hypertension in mice36 
and NK cells have been shown to play a role in endothelial 
dysfunction.37 The study of NK cells in pregnancy has princi-
pally focused on the uterine-specific population of these cells, 
Figure 4. CD161+ natural killer (NK) cells are significantly increased in pregnant stroke-prone spontaneously hypertensive rat (SHRSP). 
Flow cytometry was used to measure leukocyte populations in maternal blood (A) and placenta (B) from GD 18 Wistar–Kyoto (WKY) and 
SHRSP (n=5–6). CD3+ T cells and CD3− CD161+ NK cells were elevated in maternal blood from SHRSP relative to WKY (A; *P<0.05 vs 
WKY; **P<0.01 vs WKY). CD3− CD161+ NK cells were significantly increased in placenta from SHRSP relative to WKY (B). A representative 
dot plot showing the increase in CD3− CD161+ cells in placenta from SHRSP relative to WKY is shown in (C). NK cell numbers were 
assessed using flow cytometry in virgin (NP; n=4) and GD 18 (n=5–6) SHRSP and WKY (D; ††P<0.01 vs WKY nonpregnant [NP]; 
$$P<0.01 vs SHRSP NP). Data were analyzed by 1-way ANOVA followed by post hoc Tukey test. Th indicates T helper cell; and Tc, 
cytotoxic T cell.
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which plays an important role in remodeling the uterine spiral 
arteries in response to pregnancy.38 Changes in peripheral NK 
cells do not directly mirror the status of uterine-specific NK 
cells; therefore, the 2 populations should be considered sepa-
rately.39 In humans, the number of peripheral NK cells and 
their cytotoxicity are increased relative to nonpregnant levels 
in the first trimester followed by a decline in late pregnancy.40 
Alterations in peripheral NK cells have mostly been associ-
ated with recurrent pregnancy loss and infertility; however, 
these findings are based on relatively small, observational 
studies.39 Other small studies have also explored a proinflam-
matory shift in NK cells in preeclampsia.41 We identified that 
CD161+ cells from SHRSP produced excess TNF-α relative 
to control WKY. Although we cannot conclusively prove 
that excess TNF-α is not being produced by other cell types; 
intracellular staining for TNF-α was not significantly differ-
ent in CD3+ or other CD45+ cells. TNF-α is also produced by 
invasive extravillous trophoblasts; however, at GD 18 of preg-
nancy, trophoblasts do not exhibit potent invasive behavior.42
The presence of total CD161+ cells was increased in 
placenta from SHRSP and SHRSP treated with etanercept, 
whereas this was minimal in the WKY placenta. Therefore, 
a currently unknown TNF-α–independent mechanism exists, 
which recruits NK cells to the placenta of SHRSP. Within 
this placental CD161+ cell population, we have shown that 
etanercept induces a significant reduction in CD161 expres-
sion, which is associated with a reduction in granzyme B 
production. Conversely, this infers that TNF-α signaling is a 
critical step involved in CD161 upregulation and granzyme B 
production in NK cells. Previously, TNF-α has been shown 
to work in concert with interferon-γ to promote the cytotoxic 
activity of NK cells.43 The CD161 antibody used in this study 
detects the NKRP1A and NKRP1B cell surface receptors 
selective for NK cells. The killer ability of NK cells is pro-
tected by a sophisticated mechanism of activating and inhibi-
tory receptors, whereby the resulting action is determined by 
the balance of these signals. NKRP1A44 is an activating recep-
tor and NKPR1B an inhibitory receptor in the rat.45 CD161 is 
conserved in mice where it is also selective for NK cells46 and 
in humans where it is only expressed on a subset of NK cells.47 
Although we have shown that CD161+ NK cells are associated 
with a cytotoxic phenotype, future studies should examine the 
balance of receptors on the NK cell surface in hypertensive 
pregnancy to further define their role in pathology.
Pregnancies complicated by chronic hypertension are 
associated with an increased risk of developing serious 
pregnancy-related complications affecting both the mother 
and fetus.3 Treating women who are pregnant is challeng-
ing because of the potential effects on the fetus, and no cure 
exists for more severe hypertensive complications of preg-
nancy. Small amounts of etanercept have been shown to 
cross the placental barrier in humans; a ratio between 14:1 
and 30:1 (maternal serum:cord blood) has been reported in 
the literature.48,49 Etanercept has been used during pregnancy 
Figure 5. CD161+ cells are a source of excess TNF-α in pregnant SHRSP maternal circulation and placenta. Intracellular flow cytometry 
was used to measure TNF-α production in CD161+ natural killer cells in maternal blood (A–B) and placenta (C–D) from GD 18 WKY and 
SHRSP (n=4). CD161+ cells from the maternal circulation (A–B) and placenta (C–D) showed an increased production of TNF-α from 
pregnant SHRSP relative to WKY (* P<0.05; **P<0.01 vs WKY GD 18). Data were analyzed by Students t test.
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in women with inflammatory bowel disease and rheumatoid 
arthritis, where small studies have reported no adverse preg-
nancy outcomes,50 and in pilot studies as a treatment in early 
pregnancy for women with recurrent spontaneous miscarriage 
where it has a promising therapeutic effect.51,52 More convinc-
ing evidence of the safety of anti–TNF-α therapy in preg-
nancy will come from the ongoing Organisation of Teratology 
Information Specialists Autoimmune Diseases in Pregnancy 
Project (NCT01086059) expected to be reported in early 
2017.53
Perspectives
Excess TNF-α associated with an increase in CD161+ NK cells 
plays a causative role in abnormal vascular adaptation and 
placental biology in this preclinical model of chronic hyper-
tension in pregnancy. Etanercept ameliorates the adverse preg-
nancy outcomes associated with this model, including direct 
effects on the placenta where it reduces CD161 expression 
and granzyme B production from NK cells. Thus, etanercept 
should be considered in future studies as a promising thera-
peutic avenue for pregnancies complicated by hypertension.
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What Is New?
•	This is the first study to examine the effect of etanercept on the uterine 
vasculature during pregnancy.
•	We demonstrated that a tumor necrosis factor-α–targeted strategy re-
duces blood pressure and increases litter size in the stroke-prone spon-
taneously hypertensive rat relative to the control Wistar–Kyoto rat.
•	CD161+ natural killer cells which produce excess tumor necrosis factor-
α accumulate in the placenta of the stroke-prone spontaneously hy-
pertensive rat relative to the Wistar–Kyoto rat. Etanercept reduces the 
expression of cytotoxic granzyme B in natural killer cells found within the 
placenta of the stroke-prone spontaneously hypertensive rat.
What Is Relevant?
•	Chronic hypertension during pregnancy is an increasing problem and 
confers significant risk for both maternal and fetal morbidity and mor-
tality.
•	The role of inflammatory cytokines and immune cells has been well char-
acterized in the remodeling of the small spiral arteries of the uterus in 
response to pregnancy. Here we suggest they may also play a role in 
remodeling larger arteries.
•	Etanercept, which is currently not contraindicated for use during preg-
nancy, presents itself as a promising drug for hypertensive complications 
of pregnancy in selected cases.
Summary
TNF-α associated with an increase in CD161+ NK cells plays a 
causative role in abnormal vascular adaptation and placental biol-
ogy in this pre-clinical model of chronic hypertension in pregnancy. 
Treatment with etanercept ameliorates the adverse pregnancy 
outcomes associated with this model; including direct effects on 
the placenta where it reduces CD161 expression and granzyme B 
production from NK cells. Thus, etanercept should be considered in 
future studies as a promising therapeutic avenue for pregnancies 
complicated by hypertension.
Novelty and Significance
